Goldman Sachs Maintains Buy on Karuna Therapeutics, Raises Price Target to $109

Goldman Sachs maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and raises the price target from $35 to $109.

Benzinga · 11/18/2019 15:06

Goldman Sachs maintains Karuna Therapeutics (NASDAQ:KRTX) with a Buy and raises the price target from $35 to $109.